Shionogi goes down Niemann-Pick avenue for new cholesterol candidate
This article was originally published in Scrip
Executive Summary
Apparently preparing for the day when its substantial royalty stream from Crestor (rosuvastatin) begins to decline, Shionogi has acquired global development, manufacturing and commercialisation rights to a cholesterol-lowering candidate from Japan's Kotobuki Pharmaceutical.